1-12 of 12
James C. Gilbert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rondaptivon Pegol (BT200) to Correct Thrombocytopenia in a Peri-Interventional Setting in Type 2B Von Willebrand Disease (VWD)

Miriam Moser, Cihan Ay, Christian Schoergenhofer, James C Gilbert, Shuhao Zhu, Bernd Jilma
Journal: Blood
Blood (2024) 144 (Supplement 1): 3984.
https://doi.org/10.1182/blood-2024-202611
Published: 2024
Journal Articles

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

Alain Chion, Ciara Byrne, Ferdows Atiq, Dearbhla Doherty, Sonia Aguila, Judicael Fazavana, Patricia Lopes, Ellie Karampini, Aamir Amin, Roger J. S. Preston, Ross I. Baker, Thomas A. J. McKinnon, Shuhao Zhu, James C. Gilbert, Jonas Emsley, Bernd Jilma, James S. O’Donnell
Journal: Blood
Blood (2024) 144 (13): 1445–1456.
https://doi.org/10.1182/blood.2024024055
Published: 2024
Includes: Supplemental data
Journal Articles

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Clinical Trials & Observations
Cihan Ay, Katarina D. Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C. Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger
Journal: Blood
Blood (2023) 141 (10): 1147–1158.
https://doi.org/10.1182/blood.2022016571
Published: 2023
Includes: Supplemental data
Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Clinical Trials & Observations
Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma
Journal: Blood
Blood (2019) 133 (9): 893–901.
https://doi.org/10.1182/blood-2018-06-856930
Published: 2019
Includes: Supplemental data
Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 703.
https://doi.org/10.1182/blood.V130.Suppl_1.703.703
Published: 2017
Journal Articles

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Sandip Panicker, PhD, Christa Drucker, Sami Hussain, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD, Ulrich Jaeger, MD
Journal: Blood
Blood (2016) 128 (22): 94.
https://doi.org/10.1182/blood.V128.22.94.94
Published: 2016
Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD
Journal: Blood
Blood (2016) 128 (22): 2435.
https://doi.org/10.1182/blood.V128.22.2435.2435
Published: 2016
Journal Articles

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

Ulrich Jaeger, MD, Eileen L Rose, Andrew Singh, Sebastian H A Feickert, Simon Panzer, Bernd Jilma, MD, James C. Gilbert, MD, Sandip Panicker, PhD
Journal: Blood
Blood (2015) 126 (23): 3560.
https://doi.org/10.1182/blood.V126.23.3560.3560
Published: 2015
Journal Articles

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Petra Paulinska, MD, Bernd Jilma, MD, Christa Firbas, MD, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD
Journal: Blood
Blood (2008) 112 (11): 3374.
https://doi.org/10.1182/blood.V112.11.3374.3374
Published: 2008
Journal Articles

Proof of Concept for the Anti Von Willebrand Factor Aptamer in Patients with Relapsing Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Ji lma, MD, Petra Jilma, MD, Petra Paulinska, MD, James C. Gilbert, MD, Renta Hutabarat, PhD, Trish Wagner, Paul Knoebl, MD
Journal: Blood
Blood (2008) 112 (11): 2290.
https://doi.org/10.1182/blood.V112.11.2290.2290
Published: 2008
Journal Articles

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Chri sta Firbas, MD, Bernd Jilma, MD, Patricia G Wagner, Renta Hutabarat, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD
Journal: Blood
Blood (2008) 112 (11): 2298.
https://doi.org/10.1182/blood.V112.11.2298.2298
Published: 2008
Journal Articles

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Jilma, MD, Florian B. Mayr, MD, Paul Knoebl, MD, Alexander O. Spiel, MD, Patricia G. Merlino, Robert Schaub, PhD, James C. Gilbert, MD
Journal: Blood
Blood (2007) 110 (11): 279.
https://doi.org/10.1182/blood.V110.11.279.279
Published: 2007